Loading...
Proton-dependent inhibition of the cardiac sodium channel Na(v)1.5 by ranolazine
Ranolazine is clinically approved for treatment of angina pectoris and is a potential candidate for antiarrhythmic, antiepileptic, and analgesic applications. These therapeutic effects of ranolazine hinge on its ability to inhibit persistent or late Na(+) currents in a variety of voltage-gated sodiu...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Frontiers Media S.A.
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3689222/ https://ncbi.nlm.nih.gov/pubmed/23801963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2013.00078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|